Literature DB >> 23263202

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.

Ulf Schnetzke1, Mike Fischer, Anne-Kathrin Kuhn, Bärbel Spies-Weisshart, Elisabeth Zirm, Andreas Hochhaus, Jörg P Müller, Sebastian Scholl.   

Abstract

PURPOSE: The aim of the study was to investigate the activation of the PI3K/AKT (phosphatidylinositol-3-kinase) pathway after stimulation of TLR-4 (Toll-like receptor 4) with LPS (lipopolysaccharide) in FLT3-ITD (internal tandem duplication)-positive AML (acute myeloid leukemia) cells. TRAF6 (tumor necrosis factor receptor-associated factor 6), an E3 ubiquitin ligase, is critically involved in TLR-signaling. Based on the observation that TRAF6 might play a role in AKT phosphorylation, we hypothesized that TRAF6 can enhance the constitutive FLT3-ITD-driven activation of AKT after LPS stimulation.
MATERIALS AND METHODS: Human MV4-11 FLT3-ITD cells were silenced for TRAF6 by stable shRNA expression. Western blotting was used to analyze signal transduction by detection of phosphorylated proteins. LPS-induced activation of the NF-κB pathway was ensured by the induction of IκBα expression. To evaluate a potential functional role of TRAF6, we also performed chemosensitivity assays.
RESULTS: In MV4-11 cells, AKT was activated in response to LPS treatment. Surprisingly, shRNA-mediated knockdown of TRAF6 resulted in a significant increase in basal AKT phosphorylation. By LPS stimulation, the gain of AKT phosphorylation was more pronounced in the TRAF6 knockdown cell line than in the control. In addition, the concentration-dependent induction of apoptosis in response to treatment with the cytostatic drugs cytarabine or daunorubicin was significantly reduced in TRAF6-depleted MV4-11 cells.
CONCLUSION: Our data strongly suggest that the E3 ubiquitin ligase TRAF6 plays an important functional role in signal transduction and survival of AML cells. We hypothesize that LPS-mediated stimulation of TLR-4 leads to the induction of NF-κB-mediated signaling. However, TRAF6 might prevent a synergistic activation of the PI3K/AKT pathway after activation of TLR-4 signaling in FLT3-ITD-positive cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263202     DOI: 10.1007/s00432-012-1362-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

1.  Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Authors:  Elisabeth Zirm; Bärbel Spies-Weisshart; Florian Heidel; Ulf Schnetzke; Frank-Dietmar Böhmer; Andreas Hochhaus; Thomas Fischer; Sebastian Scholl
Journal:  Br J Haematol       Date:  2012-03-13       Impact factor: 6.998

Review 2.  Endotoxin recognition and signal transduction by the TLR4/MD2-complex.

Authors:  Katherine A Fitzgerald; Daniel C Rowe; Douglas T Golenbock
Journal:  Microbes Infect       Date:  2004-12       Impact factor: 2.700

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  TRAF6 deficiency promotes TNF-induced cell death through inactivation of GSK3beta.

Authors:  K Yoon; E J Jung; S R Lee; J Kim; Y Choi; S Y Lee
Journal:  Cell Death Differ       Date:  2008-01-18       Impact factor: 15.828

7.  Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.

Authors:  Anita Schmitt; Li Li; Krzysztof Giannopoulos; Jochen Greiner; Peter Reinhardt; Markus Wiesneth; Michael Schmitt
Journal:  Transfusion       Date:  2008-01-15       Impact factor: 3.157

8.  Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Jennifer Grosjean-Raillard; Lionel Adès; Simone Boehrer; Maximilien Tailler; Claire Fabre; Thorsten Braun; Stéphane De Botton; Alain Israel; Pierre Fenaux; Guido Kroemer
Journal:  Apoptosis       Date:  2008-09       Impact factor: 4.677

9.  TRAF6-mediated regulation of the PI3 kinase (PI3K)-Akt-GSK3beta cascade is required for TNF-induced cell survival.

Authors:  Kwiyeom Yoon; Eun Joo Jung; Soo Young Lee
Journal:  Biochem Biophys Res Commun       Date:  2008-04-11       Impact factor: 3.575

10.  Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.

Authors:  S Kasper; F Breitenbuecher; F Heidel; S Hoffarth; B Markova; M Schuler; T Fischer
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

View more
  2 in total

1.  Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6.

Authors:  Yonghao Qi; Ambara R Pradipta; Miao Li; Xuan Zhao; Lulu Lu; Xuegang Fu; Jing Wei; Richard P Hsung; Katsunori Tanaka; Lijun Zhou
Journal:  J Exp Clin Cancer Res       Date:  2017-02-23

2.  Benzoyl-xanthone derivative induces apoptosis in MCF-7 cells by binding TRAF6.

Authors:  Xuan Zhao; Limei Ren; Xiaoru Wang; Guangxin Han; Shuo Wang; Qingguo Yao; Yonghao Qi
Journal:  Exp Ther Med       Date:  2021-12-30       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.